Please login to the form below

Not currently logged in
Email:
Password:

Former GSK CEO joins Synthego’s advisory board

Sir Andrew Witty will expand the team’s bioinformatics expertise

Andrew WittyGenome engineering solutions provider Synthego has appointed Sir Andrew Witty to its advisory board, a role that will see him work on biological research and grow its application development and bioinformatics expertise.

Witty has previously served on the board of directors at GlaxoSmithKline (GSK) while he was chief executive officer (CEO) from 2008 – 2017.

He said: “Synthego’s vision for automating biological research will revolutionise the industry by accelerating application development and enabling machine learning based insights.

“Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.

“I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”

Bringing more than 30 years’ experience to Synthego, Witty’s biopharma expertise ranges from product management and business development, to strategic partnerships.

Paul Dabrowski, CEO of Synthego, said: “Andrew’s broad experience in the biopharmaceutical space will help us unlock the full value of our platform and grow in key areas of the industry.

“This is part of the next step in bringing Synthego’s bioinformatics and experimental expertise to new applications and markets.

“Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”

22nd September 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics